KRAS ANTITUMOR AGENT AND THERAPEUTIC EFFECT PREDICTION METHOD FOR PATIENTS WITH KRAS-MUTATED COLORECTAL CANCER

摘要

The present invention relates to a pharmaceutical composition comprising α, α, α-trifluorothymidine and 5-chloro-6- (1- (2-iminopyrrole Yl) methyl) ureasyl hydrochloride in a molar ratio of 1: 0.5 in order to predict the therapeutic effect of chemotherapy using an antitumor agent. (1) a step of detecting the presence or absence of a mutation of the KRAS gene contained in the biological sample collected from the patient, and (2) a step of predicting that the chemotherapy for the patient is highly likely to exhibit a sufficient therapeutic effect when the KRAS gene is mutated as a result of the confirmation in the step (1).